-
2023-504026-19-01
5
2024-06-05
Prostate Cancer
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2023-505121-14-00
5
2024-01-18
Moderate to Severe Plaque Psoriasis
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2022-503012-16-00
5
2022-07-20
Patients on treatment with Factor Xa Inhibitor needing for an urgent i
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-521295-60-00
1
2026-01-29
Sporadic Amyotrophic Lateral Sclerosis
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2023-507879-21-00
4
2026-01-19
AML and MDS undergoing allogeneic Transplantation
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2024-512503-39-00
6
2025-12-19
Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521644-37-00
4
2025-11-28
locally advanced or metastatic penile squamous cell carcinoma
-
2024-517977-26-00
5
2025-11-25
acute decompensated heart failure
-
2024-520219-42-00
10
2025-11-18
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mID